A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
=== Pre-RNA world: The ribose issue and its bypass === A different type of nucleic acid, such as peptide nucleic acid, threose nucleic acid or glycol nucleic acid, could have been the first to emerge as a self-reproducing molecule, later replaced by RNA. Larralde et al., say that "the generally accepted prebiotic synthesis of ribose, the formose reaction, yields numerous sugars without any selectivity". They conclude that "the backbone of the first genetic material could not have contained ribose or other sugars because of their instability", meaning that the ester linkage of ribose and phosphoric acid in RNA is prone to hydrolysis. Pyrimidine ribonucleosides and nucleotides have been synthesized by reactions which by-pass the free sugars, and are assembled stepwise using nitrogenous or oxygenous chemistries. Sutherland has demonstrated high-yielding routes to cytidine and uridine ribonucleotides from small 2 and 3 carbon fragments such as glycolaldehyde, glyceraldehyde or glyceraldehyde-3-phosphate, cyanamide and cyanoacetylene. A step in this sequence allows the isolation of enantiopure ribose aminooxazoline if the enantiomeric excess of glyceraldehyde is 60% or greater. This can be viewed as a prebiotic purification step. Ribose aminooxazoline can then react with cyanoacetylene to give alpha cytidine ribonucleotide. Photoanomerization with UV light allows for inversion about the 1' anomeric centre to give the correct beta stereochemistry.
In March 2010, the Center for Public Integrity released a report that Bush's administration had made more than 900 false pretenses in a two-year period about the alleged threat of Iraq against the United States, as his rationale to engage in war in Iraq.
== See also == Difluoromethyldopa D-DOPA (dextrodopa) L-DOPA (levodopa; trade names Sinemet, Pharmacopa, Atamet, Stalevo, Madopar, Prolopa, etc.) L-DOPS (droxidopa) Dopamine (Intropan, Inovan, Revivan, Rivimine, Dopastat, Dynatra, etc.) Norepinephrine (noradrenaline; Levophed, etc.) Epinephrine (adrenaline; Adrenalin, EpiPed, Twinject, etc.) MK-872 HCl salt: [55943-64-1] α-Methyltyrosine α-Methyl-5-hydroxytryptophan
Sources: en.wikipedia.org
=== Under British Raj (1858–1947) === During the 1861-65 American Civil War, American Union blockades of Southern cotton led to the Indian press speculating about the opportunity for India to export more of its cotton. The impact on the British economy also drove the construction of the Indian Railways forward, as faster transport assisted in exporting Indian cotton. In the United States, as Northerners fretted about the ultimate status of African American slaves, The New York Times argued in the weeks leading up to President Abraham Lincoln's Emancipation Proclamation that African Americans could never rise in American society above the "condition which the inferior castes of India have always occupied." India's inability to defend itself from British conquests was also referenced; Lincoln and his Secretary of State William H. Seward agreed on the need to maintain American unity in part to avoid a similar fate as that of British India, and throughout the previous decade, Southerners who sought to expand the institution of slavery to new territories referred to the rapid white conquest of places like India to justify colonizing nonwhite territories south of the United States (see also: Knights of the Golden Circle). The 1869 opening of the Suez Canal was celebrated by famous American poet Walt Whitman, who saw it as a way to connect West and East and tie into the last stage of global consolidation through American expansion.
Class Ia and III antiarrhythmics (e.g., quinidine, amiodarone, sotalol, dofetilide) Certain psychiatric medications (e.g., amitriptyline, thioridazine) Some macrolides (e.g., erythromycin) Some antihistamines (e.g., terfenadine, astemizole) Some quinolones (e.g., sparfloxacin) Other QT-prolonging drugs (e.g., cisapride) Prior use of:
In the UK (2013) DMEK is available to patients under the National Health Service at the Royal Shrewsbury Hospital, the Calderdale and Huddersfield NHS Trust, and at Worthing Hospital (Western Sussex Hospitals NHS Foundation Trust). Not all patients with diseased corneas are candidates for endothelial keratoplasty. These procedures correct corneal endothelial failure, but are not able to correct corneal scarring, thinning, or surface irregularity. There is currently limited data on long-term survival of DMEK grafts however the early indications are very positive. An upcoming systematic review will seek to compare the safety and effectiveness of DMEK versus DSAEK in people with corneal failure from Fuchs' endothelial dystrophy and pseudophakic bullous keratopathy.
Sources: en.wikipedia.org
=== Serious === Diabetic ketoacidosis, a rare but potentially life-threatening condition, may occur more commonly with empagliflozin and other SGLT-2 inhibitors. While diabetic ketoacidosis is usually associated with elevated blood glucose levels, in people taking SGLT-2 inhibitors diabetic ketoacidosis may be seen with uncharacteristically normal blood glucose levels, a phenomenon called euglycemic diabetic ketoacidosis. The absence of elevated blood glucose levels in people on an SGLT-2 inhibitor may make it more difficult to diagnose diabetic ketoacidosis. The risk of empagliflozin-associated euglycemic diabetic ketoacidosis may be higher in the setting of illness, dehydration, surgery, and/or alcohol consumption. It is also seen in type 1 diabetes who take empagliflozin, which notably is an unapproved or "off-label" use of the medication. To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Empagliflozin should each be stopped at least three days before scheduled surgery. Symptoms of diabetic ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing. Fournier's gangrene, a rare but serious infection of the groin, occurs more commonly in people taking empagliflozin and other SGLT-2 inhibitors.
A concentrate of proteolytic enzymes enriched in bromelain is approved in Europe for the debridement (removal of dead tissue) of severe burn wounds under the trade name NexoBrid. Bromelain has not been scientifically proven to be effective in treating any other diseases. Bromelain-containing dietary supplements are marketed with no confirmed efficacy, safety, recommended dosage, long term safety, or adverse interaction with other medications.
Beckman Coulter Diagnostics [1] Find out about the latest breakthroughs in clinical diagnostics and laboratory operations. SCIEX, a provider liquid chromatography-mass spectrometry instrumentation, offers P.A.C.E.® credits through its in-house training classes 4CEUINC (Continuing Education Unlimited) - Providing Online & Home Study Lab CE Courses LabCE.com Laboratory Continuing Education MediaLab, Inc. Online ASCLS P.A.C.E. credits National Laboratory Training Netword, provided through the CDC COLA LabUniversity P.A.C.E. credits
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.